Autolus Therapeutics (AUTL) FDA Announcement summary

Introduction and purpose

• FDA approved Aucatzyl (obecabtagene autoleucel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), addressing a high unmet medical need and marking a significant milestone for the company.

• Aucatzyl is the first CAR-T therapy for B-ALL approved without a REMS requirement, featuring a differentiated mechanism, fast off-rate, and customized tumor-burden-targeted dosing.

Details of approval or decision

• Approval was based on the FELIX phase 1b/2 trial, the largest CAR-T study in adult relapsed/refractory B-ALL, with 153 enrolled and three treatment arms.

• FDA analyzed 65 patients for efficacy; 51% achieved complete response, 12% had complete remission with incomplete recovery, for an overall response rate of 63%, with a median duration of response of 14.1 months.

• Commercial manufacturing will occur at the Nucleus site in the UK, with Cardinal Health as the US distributor.

Impact on industry and stakeholders

• The absence of a REMS program reduces administrative burden and streamlines onboarding for treatment centers.

• Initial launch will activate 30 centers covering about 60% of the target population, expanding to 60 centers and 90% coverage by end of 2025.

• The list price is $525,000, about 11% higher than Tecartus, reflecting clinical benefit and safety profile.

• Dedicated support services for centers, patients, and caregivers are provided through AutolusAssist.

• The Nucleus facility will supply Aucatzyl globally, supporting broader patient access.